Arthritis & Rheumatism · 1993 · 79 citations · 29 references
Life SciencesImmunologyPharmacotherapyAutoimmunityClinical ImmunologyRheumatologyAntibody ConjugatesAutoimmune DiseasesAutoimmune InflammationAutoimmune Rheumatic DiseasesImmune-related Adverse EventsRheumatoid ArthritisAzathioprine UseImmune-mediated ArthritisPhase Ii InvestigationRheumatoid Arthritis PharmacotherapyRheumatoid Arthritis Therapy
OBJECTIVE: To evaluate the safety and activity of an immunoconjugate of ricin A chain and anti-CD5 monoclonal antibody (anti-CD5 IC), with and without concomitant methotrexate and/or azathioprine, in the treatment of rheumatoid arthritis (RA). METHODS: Seventy-nine patients with active RA were enrolled in 2 prospective open-label protocols. RESULTS: Using composite criteria, response rates were 50-68% at 1 month and 22-25% at 6 months. Transient depletion of CD3/CD5 T cells was observed on days 2 and 5 of treatment, with reconstitution on day 15 or day 29. Treatment-associated adverse effects were common but resolved rapidly without sequelae. CONCLUSION: These findings suggest activity of anti-CD5 IC in active RA and warrant confirmation in a multicenter randomized study (currently underway).
29
Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis
Michael E. Weinblatt, Jonathan S. Coblyn, David A. Fox et al. · New England Journal of Medicine · 1985 · 874 citations
Weekly Pulse Methotrexate in Rheumatoid Arthritis
Sterling G. West, James R. O’Dell, Charles S. Via et al. · Annals of Internal Medicine · 1985 · 332 citations